AtriCure, Inc.
HealthcareNASDAQ:ATRC · NASDAQ Global Market
+$0.38 today
Vol 0.67M · Avg 0.77M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-2.3%
avg -9.4%
ROIC
-0.6%
avg -5.8%
ROA
-1.7%
avg -5.9%
Analysis
ROIC is currently the strongest return metric at -0.6% versus its period average of -5.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Michael H. Carrel | Chief Executive Officer, President & Director | $2.01M | — | 55 | $779,498.00 | 1.54% |
Douglas J. Seith | Chief Operating Officer | $1.25M | — | 60 | $252,288.00 | 0.50% |
Angela L. Wirick | Chief Financial Officer | $1.04M | — | 48 | $204,757.00 | 0.40% |
Justin J. Noznesky | Chief Marketing & Strategy Officer | $831,616.00 | — | 48 | $121,987.00 | 0.24% |
Salvatore Privitera | Chief Technical Officer | $825,983.00 | — | 59 | $171,175.00 | 0.34% |
Vinayak Doraiswamy | Chief Scientific Officer | $777,660.00 | — | 53 | $91,875.00 | 0.18% |
Karl S. Dahlquist CCEP | Chief Legal Officer | $707,106.00 | — | 55 | $128,318.00 | 0.25% |
Valerie Storch-Willhaus | Vice President of Corporate Marketing & Communications | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
12
$1.71M
Net Sentiment
$1.71M
Net selling
Most Active
WEHRWEIN SVEN
4 transactions
1–10 of 12
Analysis
Insiders reported 0 buys worth $0.00 and 12 sells worth $1.71M over the last 12 months. That adds up to net selling of $1.71M. WEHRWEIN SVEN was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +22.7% | +14.4% (15yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +22.7% over three years. Forward estimates point to Revenue at +14.4% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
10x Genomics, Inc.
NASDAQ:TXG
$3.66B
LeMaitre Vascular, Inc.
NASDAQ:LMAT
$2.10B
Select Medical Holdings Corporation
NYSE:SEM
$2.07B
NovoCure Limited
NASDAQ:NVCR
$2.06B
Immunocore Holdings plc
NASDAQ:IMCR
$1.47B
BioLife Solutions, Inc.
NASDAQ:BLFS
$1.28B
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
$1.22B
Xeris Biopharma Holdings, Inc.
NASDAQ:XERS
$1.17B
Azenta, Inc.
NASDAQ:AZTA
$1.04B
QuidelOrtho Corporation
NASDAQ:QDEL
$963.54M
Who manages ATRC?
AtriCure, Inc. (ATRC) lists 8 active executives. The top listed executive is Douglas J. Seith, Chief Operating Officer.
Are ATRC insiders buying or selling?
Recent insider activity shows net selling of $20.02M.
Explore More
Continue the stock analysis
Jump to another research area for this company.